Gliomas News and Research

RSS

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL.

7 Jun 2010

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the United Kingdom, reported positive final data from an investigator-sponsored Phase 1 study of OXi4503 in patients with solid tumors.

7 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Patients with high-grade gliomas who experience acute (early) neurological toxicity during their treatment were more likely to experience chronic (late) neurological toxicity and shortened overall survival, according to researchers from the Kimmel Cancer Center at Jefferson. The study will be presented at the 2010 ASCO Annual Meeting in Chicago (Abstract #2037).

5 Jun 2010

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

PDGFRA gene may lead to effective treatments for paediatric high grade glioma: Study

Scientists have discovered a gene that could lead to more effective treatments for a form of childhood brain cancer called paediatric high grade glioma.

21 May 2010

Study explores genetic imbalances that give rise to childhood brain tumors

The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.

21 May 2010

Caregivers can give complete clinical picture of brain cancer patients' condition

Despite grim prognoses and aggressive treatments, cancer patients suffering from malignant gliomas -- primary brain tumors -- often rate their quality of life more optimistically than their caregivers do, according to a new Northwestern University Feinberg School of Medicine study.

21 May 2010

Researchers identify cancer gene that could help fight paediatric glioma

Researchers have identified an important cancer gene that could lead to more effective drugs being developed to fight paediatric high grade glioma, a disease which currently has a poor prognosis.

19 May 2010

Interphone Study underestimates risk of brain cancer, says International EMF Collaborative

Authors of the report, "Cellphones and Brain Tumors: 15 Reasons for Concern, Science, Spin and the Truth Behind Interphone" have released a technical analysis of the long-awaited Interphone Study published today in the International Journal of Epidemiology.

18 May 2010

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives, according to researchers at Thomas Jefferson University.

18 May 2010

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Gliomas arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). These tumors are graded from the lowest grade 1 to highest grade 4, with glioblastoma multiforme being the highest grade and deadliest type of glioma.

7 May 2010

Researchers explore role of ECoG measurement to improve brain mapping technology

Epilepsy and seizures affect nearly 3 million Americans of all ages, with 200,000 new cases of seizures and epilepsy occurring each year. Epilepsy surgery may be performed in patients who have seizures associated with structural brain abnormalities, such as benign brain tumors and cortical dysplasia, malformations of blood vessels, the genetic disorder tuberous sclerosis, and strokes.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.

23 Apr 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

22 Apr 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

21 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

DNA modification can define early onset glioblastoma

A class of brain tumor that tends to emerge in younger patients but is less aggressive than others can be identified by examining DNA methylation of a specific set of genes, scientists at The University of Texas M. D. Anderson Cancer Center and colleagues with The Cancer Genome Atlas report today online at Cancer Cell.

16 Apr 2010

Brain stem cells in subventricular zone characterized by transcription factor Protein Tlx

The "cradle" of new neurons in the adult brain is well known. It is what is called the subventricular zone, a tissue structure lining the lateral ventricles. This is where neural or brain stem cells reside, which are responsible for generating new neurons if needed. For many years now, the subventricular zone has been suspected to be the origin of specific malignant brain tumors called gliomas, the most deadly type of which is glioblastoma.

2 Apr 2010

Gliomas News and Research

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

New clinical research findings on oncology to be highlighted at ASCO 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

2010 ASCO Annual Meeting highlights new research findings on cancer

PDGFRA gene may lead to effective treatments for paediatric high grade glioma: Study

Study explores genetic imbalances that give rise to childhood brain tumors

Caregivers can give complete clinical picture of brain cancer patients' condition

Researchers identify cancer gene that could help fight paediatric glioma

Interphone Study underestimates risk of brain cancer, says International EMF Collaborative

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Researchers explore role of ECoG measurement to improve brain mapping technology

Novel combined immunotherapy promising for treatment of malignant brain tumors

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

DNA modification can define early onset glioblastoma

Brain stem cells in subventricular zone characterized by transcription factor Protein Tlx

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News